2cureX presented progression in the IndiTreat® immuno-oncology assay development at the ESMO Immuno-Oncology Congress in Geneva 11-14 Dec. 2019.
2cureX AB (“2cureX”, NASDAQ: 2CUREX) announces that the company presented significant progression of the IndiTreat® test for individualizing immuno-oncological treatment at the ESMO IO Congress. This development project is funded by the German Federal Ministry of Education and Research and is conducted in collaboration with the University Medical Center Hamburg-Eppendorf (Universitätsklinikum Hamburg-Eppendorf, UKE).Immuno-oncology (I-O) therapy for different types of cancer has contributed significantly to the cancer treatment landscape and is among the fastest growing areas within